ArticleScientific reports2024
The impact of metabolic component count on IgA nephropathy prognosis.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Visceral Obesity and Metabolic Dysfunction in IgA Nephropathy: Nutritional and Metabolic Perspectives on Disease Progression.Nutrients · 2025Pooled it
- The triglyceride-glucose index as an independent associate of severe tubulointerstitial fibrosis and a predictor of renal survival in IgA nephropathy.Frontiers in endocrinology · 2026Article
- Cholesterol, high-density lipoprotein, and glucose index is associated with renal survival in patients with IgA nephropathy.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic syndrome, a cluster of conditions including obesity, hyperglycemia, hypertension, and dyslipidemia, is increasingly recognized for its association with kidney disease. However, the impact of metabolic syndrome on the long-term prognosis of IgA nephropathy(IgAN) remains understudied. From August 2009 to December 2018, we conducted a retrospective cohort study at the Department of Nephrology, General Hospital of Ningxia Medical University, involving 698 patients with primary IgAN identified by the initial renal biopsy. Patients were divided into five groups based on the number of metabolic syndrome components they exhibited, including metabolic syndrome with hyperuricemia: Group A (no components), Group B (one component), Group C (two components), Group D (three components), and Group E (four or more components). We compared and analyzed the effect of metabolic components on the prognosis of IgAN. The mean age was 35.83 years, and 51.86% male. The prevalence of metabolic syndrome was 25.07%. The 24-h urine protein quantification correlated positively with metabolic components (P < 0.05), while eGFR correlated negatively (P < 0.05). Kaplan--Meier analysis showed decreased renal survival with more metabolic components, especially with four or more (P < 0.001). Blood pressure was the most important factor influencing the occurrence of endpoint events in IgAN patients, according to a random forest technique analysis. The incidence of metabolic abnormalities in patients with IgA nephropathy is closely related to the severity of clinical manifestations and poor renal prognosis, with blood pressure being the most critical factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.